Posted on

MYND Life Sciences makes progress in treating Alzheimer’s and dementia with psilocybin

MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with Chemical Subclasses of Psilocybin Analogues

You won’t want to forget about this company when choosing your investments. The research team at MYND Life Sciences Inc. (MYND) has been exploring new subclasses of psilocybin that have shown potential to delay or reverse Alzheimer’s disease and other forms of dementia. The preclinical research has shown significant progress, and MYND aims to commence clinical trials to advance the research.

PDF of article

Posted on

Nova Mentis receives approval for autism clinical study

Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

Are psychedelics the future of autism treatment? Nova Mentis Life Sciences Corp. (NOVA) received Canadian approval for a new study on autism, which will be the first step in bringing psilocybin treatment to autistic patients. Researchers will observe 200 patients with autism spectrum disorder (ASD) or fragile x syndrome (FXS) to establish baseline biomarkers that can be used to measure psilocybin treatment responses in a later study. NOVA will monitor the gut microbiome, immune response, and serotonin activity in patients, as these factors influence behavioural symptoms.

PDF of article

Posted on

Red Light Holland will acquire 51% stake in Acadian Exotic Mushrooms Ltd.

Red Light Holland to Partner with Leading Fresh and Dried Mushroom Producers on East Coast Facility

Red Light Holland Corp. (TRIP), an Ontario-based company that sells truffles in the Netherlands, will acquire 51% of Acadian Exotic Mushrooms Ltd. (AEM), a mushroom production facility that is expected to produce 5,000 lbs of Shiitake mushrooms per week. Red Light Holland’s CEO, Todd Shapiro is excited to have another revenue generating farm, which has potential to serve as a psilocybin production site in the future. Shapiro envisions throwing concerts on the land, a 4 acre plot in Eel River Crossing, New Brunswick.

PDF of article

Posted on

Psychedelic therapy retreat aims to use psilocybin to treat traumatic brain injury (TBI) in veterans

Ground-breaking research to explore the potential for psilocybin to treat traumatic brain injury

This Fall, Heroic Hearts Project will begin psychedelic therapy retreats in the Netherlands and Jamaica to study the effect of psilocybin on veterans with traumatic brain injury (TBI). Many veterans sustain brain injuries during their service, which can lead to issues like anxiety, depression, and substance abuse. The retreats aim to study both the psychological and physiological impacts of psilocybin therapy.

PDF of article

Posted on

Mydecine’s psychedelic compound shows “blockbuster potential”, according to Roth Capital Partners

Roth says Mydecine Innovations has blockbuster potential with its MYCO-001 psychedelic therapy as it initiates coverage

Roth Capital Partners, a private investment bank in California, gave Mydecine Innovations Group Inc. (MYCO) a ‘buy’ rating with a C$3  target based on the “blockbuster potential” of its pyschedelic compound, MYCO-001. Mydecine expects to complete advanced clinical trials for PTSD and smoking cessation within the next 18-24 months. Based on this timeline, Roth believes that MYCO-001 could be introduced to the US market for smoking cessation in 2026, and could reach $2.5 billion in sales by 2031 by capturing just 0.5% market. Roth predicts that MYCO-001 will take over 20% of the market for PTSD treatment by 2032, reaching $3 billion in sales.

PDF of article

Posted on

PsyBio Therapeutics (PSYB) begins manufacturing in France

PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie

PsyBio Therapeutics Corp. (PSYB), a Florida-based biotech company, began manufacturing their biosynthetic psilocybin formulations for further testing at a certified facility in France. PsyBio partnered with Biose Industrie to support their European expansion, a company with over 70 years of experience in commercializing pharmaceuticals with live bacterial strains. “Our partnership with Biose will further our research and development goals and demonstrate our commitment to the development of globally-tested and approved therapeutics,” PsyBio’s Chief Medical Officer stated.

PDF of article

Posted on

Patient overcomes childhood trauma through psilocybin therapy, easing her anxiety and fear of death

B.C. health researchers harness the ‘magic’ of psychedelic mushrooms

After beating cancer, Mona Strelaeff suffered from crippling depression and anxiety rooted in childhood trauma and a fear of death. She tried several anti-depressants with extreme side effects before receiving approval for psilocybin-assisted therapy. The experience allowed her to come to terms with childhood demons. “When [the doctor] gave me the treatment and I came out of it in a place of peace,” she said. “My anxiety was basically gone. And to this day I still feel at peace. I’m not afraid of death.”

PDF of article

Posted on

Research shows psilocybin’s potential to treat cocaine addiction and chronic pain

Magic mushrooms: UAB studying benefits for addiction and pain

Dr. Peter Hendricks, a researcher at the University of Alabama in Birmingham, found that patients given psilocybin saw significant and lasting reductions in cocaine use compared to patients given a placebo. He plans to continue studying psilocybin’s effect on addiction, as well as on chronic pain conditions like fibromyalgia. Hendricks explains that psilocybin disrupts repetitive thought patterns in the default mode network of the brain, the structures that engage in unfocused activities. “Suddenly your horizons are broadened, and broadened tremendously, and you’re thinking about something other than obtaining or using that drug (or worrying about your pain)”.

PDF of article